stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
34.81
2.28
+7.01%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Net income
Pharvaris N.V.'s net income for fiscal 2025 was −$196.5M, compared with −$143.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$193.1M. Over the past ten years it has ranged from −$196.5M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 8 consecutive fiscal years. Pharvaris N.V. ranks 515th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$196.5M | — |
| FY2024 | −$143.3M | — |
| FY2023 | −$108.0M | — |
| FY2022 | −$79.7M | — |
| FY2021 | −$50.5M | — |
| FY2020 | −$29.8M | — |
| FY2019 | −$9.0M | — |
| FY2018 | −$5.1M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$54.6M | — |
| Mar 2026 | −$45.6M | — |
| Dec 2025 | −$46.2M | — |
| Sep 2025 | −$46.7M | — |
| 20 more quarters | Free account |
Against its own ten years
Low −$196.5M
High $0.00
Ten-year median
−$50.5M
Current reading's percentile
11
Net income against peers
| Company | Net income |
|---|---|
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| PHVS Pharvaris N.V. | −$193.1M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$204.9M |
| IMNM Immunome, Inc. compare | −$254.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$475.7M |
| BHVN Biohaven Ltd. compare | −$542.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item